UroGen Pharma (URGN) announced the grants of inducement restricted stock units to 40 new employees in connection with their employment with UroGen. These new team members will support the ongoing commercialization of Jelmyto for pyelocalyceal solution and ZUSDURI for intravesical solution, UroGen’s only approved products, and the continued development of UroGen’s pipeline. Up to 67,700 ordinary shares of UroGen are issuable upon the vesting and settlement of the RSUs. The RSUs will vest equally over three years, with one-third of the underlying shares vesting each year on the anniversary of the vesting date, subject in each case to the employee’s continued service relationship with UroGen.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on URGN:
- UroGen Pharma Shareholders Approve Key Proposals at Meeting
- Piper starts ‘underestimated’ UroGen Pharma with an Overweight
- UroGen Pharma initiated with an Overweight at Piper Sandler
- UroGen Pharma’s Earnings Call: Achievements and Challenges
- UroGen Pharma price target lowered to $40 from $50 at H.C. Wainwright